Atea Pharmaceuticals Correlations

AVIR Stock

USD 3.37 0.12 3.69%

The current 90-days correlation between Atea Pharmaceuticals and Immix Biopharma is 0.25 (i.e., Modest diversification). The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Atea Pharmaceuticals Correlation With Market

Very weak diversification

The correlation between Atea Pharmaceuticals and DJI is 0.56 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Atea Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Moving together with Atea Stock

0.71	VALN	Valneva SE ADR	Pair Corr
0.63	VCNX	Vaccinex	Pair Corr
0.74	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.69	LLY	Eli Lilly Sell-off Trend	Pair Corr
0.75	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.62	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.79	GMAB	Genmab AS	Pair Corr
0.74	INZY	Inozyme Pharma	Pair Corr
0.79	IPSC	Century Therapeutics	Pair Corr
0.65	KRYS	Krystal Biotech	Pair Corr
0.68	LEGN	Legend Biotech Corp	Pair Corr
0.66	LYRA	Lyra Therapeutics	Pair Corr
0.78	NKTX	Nkarta Inc	Pair Corr
0.61	NUVB	Nuvation Bio	Pair Corr

Moving against Atea Stock

0.72	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.62	EWTX	Edgewise Therapeutics	Pair Corr
0.61	GILD	Gilead Sciences	Pair Corr
0.48	KZR	Kezar Life Sciences	Pair Corr
0.45	VRDN	Viridian Therapeutics	Pair Corr
0.66	MNPR	Monopar Therapeutics	Pair Corr
0.61	AMLX	Amylyx Pharmaceuticals	Pair Corr
0.6	RVMD	Revolution Medicines Sell-off Trend	Pair Corr
0.49	AKRO	Akero Therapeutics	Pair Corr
0.49	SRZN	Surrozen	Pair Corr

Related Correlations Analysis

	IMMX	CNSP	HEPA	FRLN	AVRO	ENVB	CWBR	ELEV	OCEA	EFTR
IMMX		0.71	0.81	0.75	-0.05	0.49	-0.62	0.87	0.33	0.47	IMMX
CNSP	0.71		0.67	0.51	-0.38	0.6	-0.57	0.77	0.57	0.62	CNSP
HEPA	0.81	0.67		0.62	-0.16	0.45	-0.48	0.74	0.42	0.41	HEPA
FRLN	0.75	0.51	0.62		0.12	0.05	-0.33	0.75	-0.09	0.4	FRLN
AVRO	-0.05	-0.38	-0.16	0.12		-0.14	0.36	-0.06	-0.64	-0.26	AVRO
ENVB	0.49	0.6	0.45	0.05	-0.14		-0.41	0.52	0.64	0.38	ENVB
CWBR	-0.62	-0.57	-0.48	-0.33	0.36	-0.41		-0.45	-0.46	-0.28	CWBR
ELEV	0.87	0.77	0.74	0.75	-0.06	0.52	-0.45		0.34	0.6	ELEV
OCEA	0.33	0.57	0.42	-0.09	-0.64	0.64	-0.46	0.34		0.43	OCEA
EFTR	0.47	0.62	0.41	0.4	-0.26	0.38	-0.28	0.6	0.43		EFTR
	IMMX	CNSP	HEPA	FRLN	AVRO	ENVB	CWBR	ELEV	OCEA	EFTR

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

ELEV	+ 0.87	IMMX
HEPA	+ 0.81	IMMX
ELEV	+ 0.77	CNSP
FRLN	+ 0.75	IMMX
ELEV	+ 0.75	FRLN
ELEV	+ 0.74	HEPA

High negative correlations

OCEA	- 0.64	AVRO
CWBR	- 0.62	IMMX
CWBR	- 0.57	CNSP
CWBR	- 0.48	HEPA
OCEA	- 0.46	CWBR
ELEV	- 0.45	CWBR

Risk-Adjusted Indicators

There is a big difference between Atea Stock performing well and Atea Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Atea Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
IMMX	3.87	(0.35)	0.00	(0.14)	0.00	0.00	7.06	(8.22)	32.68
CNSP	4.99	(0.47)	0.00	(0.17)	0.00	0.00	9.09	(11.76)	39.29
HEPA	3.82	(0.35)	0.00	(0.15)	0.00	0.00	8.06	(8.11)	33.54
FRLN	5.90	0.09	0.00	0.06	0.00	0.00	14.23	(13.11)	72.38
AVRO	1.77	0.18	0.01	(0.49)	1.89	(2.24)	4.11	(3.17)	14.20
ENVB	3.21	(0.58)	0.00	2.51	0.00	0.00	6.25	(7.50)	28.33
CWBR	7.34	2.25	0.33	1.40	5.34	(11.19)	5.73	(5.59)	250.97
ELEV	3.51	(0.59)	0.00	(0.17)	0.00	0.00	5.77	(8.22)	22.21
OCEA	3.56	(0.56)	0.00	(1.39)	0.00	0.00	7.46	(6.93)	28.33
EFTR	7.57	(4.50)	0.00	8.68	0.00	0.00	8.70	(27.78)	88.91

Atea Pharmaceuticals Corporate Management

CPA CPA	Exec Officer	Profile
XiaoJian Zhou	Executive Development	Profile
Jayanthi Wolf	Executive Affairs	Profile
Wayne CPA	Executive Officer	Profile
Ariyapadi Krishnaraj	Vice Marketing	Profile
JeanPierre Sommadossi	Chairman, Founder	Profile
John Vavricka	Chief Officer	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC